Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Open access

Abstract

Background Chronic heart failure is associated with high mortality and morbidity. Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure.Methods Patients were eligible for participation in this randomised, double-blind, placebo-controlled, parallel-group study if they had symptomatic heart failure and a left-ventricular ejection fraction of 35% or lower, were in sinus rhythm with heart rate 70 beats per min or higher, had been admitted to hospital for heart failure within the previous year, and were on stable background treatment including a β blocker if tolerated. Patients were randomly assigned by computer-generated allocation schedule to ivabradine titrated to a maximum of 7.5 mg twice daily or matching placebo. Patients and investigators were masked to treatment allocation. The primary endpoint was the composite of cardiovascular death or hospital admission for worsening heart failure. Analysis was by intention to treat. This trial is registered, number ISRCTN70429960.Findings 6558 patients were randomly assigned to treatment groups (3268 ivabradine, 3290 placebo). Data were available for analysis for 3241 patients in the ivabradine group and 3264 patients allocated placebo. Median follow-up was 22.9 (IQR 18-28) months. 793 (24%) patients in the ivabradine group and 937 (29%) of those taking placebo had a primary endpoint event (HR 0.82, 95% CI 0.75-0.90, p<0.0001). The effects were driven mainly by hospital admissions for worsening heart failure (672 [21%] placebo vs 514 [16%] ivabradine; HR 0.74, 0.66-0.83; p<0.0001) and deaths due to heart failure (151 [5%] vs 113 [3%]; HR 0.74, 0.58-0.94, p=0.014). Fewer serious adverse events occurred in the ivabradine group (3388 events) than in the placebo group (3847; p=0.025). 150 (5%) of ivabradine patients had symptomatic bradycardia compared with 32 (1%) of the placebo group (p<0.0001). Visual side-effects (phosphenes) were reported by 89 (3%) of patients on ivabradine and 17 (1%) on placebo (p<0.0001).Interpretation Our results support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the important role of heart rate in the pathophysiology of this disorder.Funding Servier, France.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)61198-1

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 26 references

Cited by

See all 2,563

Metadata

Authors
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L.
Affiliations
  • University of Gothenburg (SE)
  • Universitätsklinikum des Saarlandes (DE)
  • SUNY Downstate Health Sciences University (US)
  • University of Glasgow (GB)
  • Institut de Recherches Internationales Servier (France) (FR)
  • Maria Cecilia Hospital (IT)
Corresponding author
Swedberg, Karl
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-09
Volume
376
Issue
9744
Pages
875-885
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2136642260
Cited by
2,563
References
26
Citations by year
2026: 64 · 2025: 100 · 2024: 118 · 2023: 132 · 2022: 154 · 2021: 192 · 2020: 190 · 2019: 162 · 2018: 163 · 2017: 220 · 2016: 241 · 2015: 186 · 2014: 139 · 2013: 179 · 2012: 165
FWCI
108.23
Type
journal article
Language
en
Update notices
erratum (2010-12-11)
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • ORBi (University of Liège) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Keywords
ivabradine, chronic heart failure, heart rate reduction, cardiovascular mortality, heart failure with reduced ejection fraction, beta-blocker therapy, serious adverse events, SHIFT trial, drug safety and efficacy
MeSH terms
Ivabradine, Adult, Aged, Benzazepines, Cardiovascular Agents, Chronic Disease, Double-Blind Method, Electrocardiography, Female, Heart Failure, Heart Rate, Humans, Male, Middle Aged, Severity of Illness Index, Sinoatrial Node, Treatment Outcome, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(10)61198-1
The paper
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010). Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(10)61198-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.